Member Info for shandypants2

and finally the share price responds. Hopefully 40p by xmas

gotta be close now. CEO said it may not be completed by end of Sept, so i'm expecting it by end of Oct at the latest.
Keep the faith!!!

been a steady rise the last few days and now over $11k. Onwards and upwards - please!!!

agreed Thompi. Heavily discounted small placing and no great positivity. Can't see a Japanese deal every happening - surely we need to seek other partners.
Chairman clearly doesn't want to work full time for company - did they not know they needed a CEO when last one left?

nice buying in last few hours - maybe US news soon??

warrants are essentially mini placings. New shares are added at a fixed price, usually less than the current price else not much point exercising them.
The company gains as they get the money, but shareholders suffer a small dilution as there are now more shares in total.
Warrants are usually issued when a placing is undertaken - usually at a higher price than the placing price.
Personally i'm not overly keen on them as it allows those who participated in the placing to benefit twice - initially when they receive placing shares at a discount to the current price and then potentially later if the share price increases.
For SKIN as number of warrants is a small fraction of total shares in issue impact is minimal really.

what a negative post. There is room for many products, so having competitors is surely good. This is a world wide pandemic

If, and it is a big if, a vaccine is discovered how will it be scaled up to service everyone? Priority for vulnerable people will be given.

SKIN are in the right space - the water detection is a fantastic place to be.

The breathalyser may succeed but if it doesn't SKIN is still well positioned

yes, getting US and Oz revenues up is very important.

Hopefully we should see more nuthing deals in the coming months.

Progress on prolong is long overdue too

brave to be buying Rev or IDP??

but market cap already £200m. A lot of the upside is already priced in.

Having said that 450p seems a reasonable price IMHO

hopefully gold too!!!

Moni - as an ex Hvivo shareholder i understand that you are bitter. However, since the takeover you have seen your shares increase from 5p to 15p and hopefully 20p plus in the not too distant future.

Surely, even you must admit that CF is doing something right

really need some positives to get this on people's radar as there seems little interest (other than Mr Ward).

What's going on re CEO search
Expansion of ST outside UK
Ditto Nuthing
Roots relaunch
Prolong progress - has Far Eastern order been completed or is regulatory approval still outstanding (possible with covid etc)

Also progress since YE as we should have nearly 3 months worth of revenue.

It's clear Joe Bayer wants to run the company after getting rid of Callan so he needs to show us shareholders he has a plan and is delivering to it

It's from the RNS back in Sept 2018 when we announced the agreement with Norgine.
It does mention net sales - so not sure what gets deducted before the royalties are applied.
I've copied the main excerpt below, to save you searching.
In the Feb 2020 presentation STX estimated 5% of US market was worth £821m NPV to STX , based on the same royalty levels as Europe.

Shield Therapeutics and Norgine B.V. (Norgine) enter into an exclusive licence agreement for the commercialisation of Feraccru® in Europe, Australia and New Zealand



· Shield to receive an £11 million upfront licence payment

· Up to €54.5million in development and sales milestones, together with royalties ranging from 25% to 40%

· Shield retains full commercial rights to Feraccru® in all unlicensed countries including the USA



London, UK, 19 September 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs and Norgine, a leading European specialist pharma company, today announced that they have entered into an exclusive licence agreement in Europe, Australia and New Zealand by which Norgine will commercialise Feraccru®, Shield's approved product for the treatment of iron deficiency in adults.



Under the terms of the agreement, Shield will receive an immediate £11 million upfront payment, is eligible to receive up to €4.5 million in short-term development milestones and up to €50 million in sales milestones upon the achievement of specified targets. Shield will also receive tiered royalties ranging from 25% to 40% of net sales of Feraccru®.

European royalties are c25% i think , so expect US to be in the same ball park

was hoping for nearer 50p, but based on share price in few months before offer (so 32 to 35p) it's a reasonable premium.

May wait until deal is concluded on 19th Oct as i'd rather have the extra money. Only a few hundred ££ difference, but it all counts

https://www.proactiveinvestors.co.uk/companies/news/900636/shield-therapeutics-encouraged-by-us-interest-in-iron-deficiency-treatment-900636.html

decent summary - analysts believe US opportunity is worth $1bn alone. Enough said IMHO

i hope you paid 5.5p else you've been ripped off!!! Under 6p is a fantastic price BTW

a credit facility is a loan - it needs to be repaid. Essentially the merger is 2 loss making companies being combined - short term they will lose more money as a combined entity. Clearly the water detection could be a game changer - but any orders need to be manufactured, which costs money

As per today's RNS not sure why a guy who's worked in retail and car parks etc would want/be selected to be CEO of a very small oiler. Over the last 10 years have we ever sold a barrel of oil yet?

Greg Bandy - B.Com

Managing Director

Greg Bandy has nearly 20 years of experience in retail, corporate and capital markets, both in Australia and overseas. Mr. Bandy worked as a Senior Client Advisor at Montagu Stockbrokers and Patersons Securities for over 10 years before moving to the corporate sector. A former director of Empire Beer Group Limited, Mr. Bandy oversaw the acquisition of Car Parking Technologies (now Smart Parking Limited (ASX: SPZ)) before stepping down as Executive Director. Mr. Bandy is also the former Managing Director of Fin Resources Limited (ASX: FIN).